Creatine entering dendritic cells via the Slc6a8 transporter increases their energy storage, which raises levels of activation markers and inflammatory signals and improves their ability to activate CD8+ T cells in both mice and humans.
See the scientific wording
Creatine uptake through the creatine transporter (Slc6a8) in dendritic cells enhances intracellular ATP buffering, which increases the expression of activation markers (CD86, I-Ab), proinflammatory cytokines (TNF-α, IL-6), and improves the priming of antigen-specific CD8+ T cells in mouse and human models.
Correlational — new studies may shift this
ObservationalOne moderate-quality study links this claim to the outcome, but causation is not established.
What the research says
1 study reviewedSupporting (1)
Creatine uptake promotes dendritic cell activation and enhances antitumor immunity
Cohort StudyHuman2026
Dendritic cells use creatine like a battery to stay energized, which helps them sound the alarm better against cancer. When scientists gave creatine to these cells in mice and humans, they became more active and better at training immune cells to fight tumors.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Dendritic cells take in creatine through a specific transporter, which they use to store and quickly release energy. This keeps their energy levels high when they need to sound the alarm about cancer. With enough energy, they turn on genes that make them more active and release signals that teach immune cells to attack tumors. Without this creatine system, dendritic cells run out of energy, fail to activate properly, and cannot train immune cells to fight cancer.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Creatine entering dendritic cells via the Slc6a8 transporter increases their energy storage, which raises levels of activation markers and inflammatory signals and improves their ability to activate CD8+ T cells in both mice and humans.
Mechanism
1 studyDendritic cells use creatine as an energy reserve to stay active when fighting cancer. This energy keeps them turning on alarm signals and teaching immune cells to attack tumors. Without creatine, they run out of power and fail to trigger an effective immune response.
Dendritic cells take in creatine through a specific transporter, which they use to store and quickly release energy. This keeps their energy levels high when they need to sound the alarm about cancer. With enough energy, they turn on genes that make them more active and release signals that teach immune cells to attack tumors. Without this creatine system, dendritic cells run out of energy, fail to activate properly, and cannot train immune cells to fight cancer.
Dendritic cells increase expression of the creatine transporter Slc6a8 in response to inflammatory signals such as TLR ligands or TNF-α
Creatine is transported into dendritic cells and converted to phosphocreatine, forming a high-energy phosphate reservoir
The creatine/phosphocreatine system maintains intracellular ATP levels during periods of high energy demand, preventing depletion and suppressing AMP:ATP and ADP:ATP ratios
Sustained ATP levels enable continuous phosphorylation and nuclear translocation of NF-κB p65 through activation of IKKβ and IκBα
Activated NF-κB drives transcription of genes encoding costimulatory molecules CD86 and I-Ab and proinflammatory cytokines TNF-α and IL-6
Dendritic cells with elevated activation markers and cytokine production enhance antigen presentation to CD8+ T cells, increasing their proliferation, cytokine secretion, and expression of activation markers CD25 and CD69
Primed CD8+ T cells infiltrate tumors and exert cytotoxic activity, leading to suppression of tumor growth
Evidence from Studies
Supporting (1)
Community contributions welcome
Creatine uptake promotes dendritic cell activation and enhances antitumor immunity
Dendritic cells use creatine like a battery to stay energized, which helps them sound the alarm better against cancer. When scientists gave creatine to these cells in mice and humans, they became more active and better at training immune cells to fight tumors.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Creatine Supplementation Effects on Dendritic Cell Activation and CD8+ T Cell Priming in Cancer Models
Population: Human and mouse dendritic cells and CD8+ T cells in tumor contexts; Intervention: Creatine supplementation via Slc6a8; Comparator: Slc6a8 knockout or creatine-depleted conditions; Outcome: Expression of CD86, I-Ab, TNF-α, IL-6, and CD8+ T cell activation; Duration: Chronic exposure across multiple tumor models.
Double-Blind Placebo-Controlled Trial of Creatine on Dendritic Cell Activation and T Cell Priming in Cancer Patients
Population: Adults with solid tumors; Intervention: Oral creatine monohydrate; Comparator: Placebo; Outcome: Flow cytometry of dendritic cell CD86/I-Ab, serum TNF-α/IL-6, and tumor-infiltrating CD8+ T cell frequency and activation; Duration: 12 weeks.
Prospective Cohort Study of Creatine Metabolism and Dendritic Cell Function in Cancer Patients Over Time
Population: Cancer patients with serial blood and tumor biopsies; Intervention: None (observational); Comparator: High vs. low Slc6a8 expression; Outcome: Changes in dendritic cell markers, cytokine levels, and CD8+ T cell responses over 6–12 months; Duration: Longitudinal follow-up.
In Vitro Analysis of Creatine Transport via Slc6a8 on Dendritic Cell ATP Buffering and T Cell Priming Capacity
Population: Human and mouse dendritic cells isolated from spleen or blood; Intervention: Creatine exposure with or without Slc6a8 inhibition; Comparator: Slc6a8-knockdown or creatine-free medium; Outcome: Intracellular ATP levels, CD86/I-Ab expression, TNF-α/IL-6 secretion, and co-cultured CD8+ T cell proliferation; Duration: 24–72 hours.
Mouse Model Study of Slc6a8 Knockout on Tumor Growth, Dendritic Cell Function, and CD8+ T Cell Priming
Population: Wild-type and Slc6a8-knockout mice with transplanted tumors; Intervention: None (genetic manipulation); Comparator: Slc6a8-deficient vs. wild-type dendritic cells; Outcome: Tumor growth, dendritic cell activation markers, cytokine levels, and tumor-infiltrating CD8+ T cell numbers and function; Duration: 3–6 weeks.